Arrowhead Reports Positive Phase 3 Data for Plozasiran in Hypertriglyceridemia Trial
Arrowhead Pharmaceuticals announced that its experimental drug plozasiran significantly reduced acute pancreatitis episodes in Phase 3 trials for patients with severe hypertriglyceridemia. The company now intends to submit a regulatory filing based on these clinical findings.